Vitiligo
📧 Sign up to get email alerts when something new happens for Vitiligo.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-03EMA Authorised: Opzelura (ruxolitinib phosphate) — Incyte Biosciences Distribution B.V.
EMA has authorised Opzelura (ruxolitinib phosphate) for use in vitiligo and atopic dermatitis, with Incyte Biosciences Distribution B.V. as …
-
EMA approval · 2026-07-22EMA Authorised: Opzelura (ruxolitinib phosphate) — Incyte Biosciences Distribution B.V.
EMA has authorised Opzelura (ruxolitinib phosphate) for the treatment of vitiligo in the EU.
-
EMA approval · 2026-06-15EMA Authorised: Opzelura (ruxolitinib phosphate) — Incyte Biosciences Distribution B.V.
The EMA has authorised Opzelura (ruxolitinib phosphate) for a therapeutic area focusing on vitiligo, with Incyte Biosciences Distribution B.…
-
EMA approval · 2026-03-23EMA Authorised: Opzelura (ruxolitinib phosphate) — Incyte Biosciences Distribution B.V.
The European Medicines Agency authorised Opzelura (ruxolitinib phosphate) for the treatment of vitiligo, with decision dated 26 February 202…
-
FDA approval · 2024-01-08FDA Approved: METHOXSALEN — Supplemental Application (Strides Pharma Science Limited)
The FDA approved a supplemental application for methoxsalen submitted by Strides Pharma Science Limited. This action updates the approved la…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.